🔴 Website 👉 https://u-s-news.com/
Telegram 👉 https://t.me/usnewscom_channel
OAN Staff Brooke Mallory
6:39 PM – Tuesday, February 17, 2026
In a strategic move to contain one of the most litigious chapters in corporate history, Bayer’s subsidiary, Monsanto, announced a proposed $7.25 billion nationwide class-action settlement on Tuesday — aiming to resolve the vast majority of current and future claims related to its Roundup weedkiller causing non-Hodgkin lymphoma (NHL).
According to the Bayer CEO, the proposal comes as Bayer attempts to find a “path out of litigation uncertainty” that has plagued the company since its $63 billion acquisition of the controversial Monsanto company in 2018. If granted preliminary approval by the Circuit Court of St. Louis, the settlement would establish a long-term claims program with several defining features.
“The proposed class settlement agreement, together with the Supreme Court case, provides an essential path out of the litigation uncertainty and enables us to devote our full attention to furthering the innovations that lie at the core of our mission: Health for all, Hunger for none,” said Bill Anderson, CEO of Bayer.
“This litigation and the resulting cost underscore the need for guidance from the Supreme Court on clear regulation in American agriculture. The class settlement and Supreme Court case are both necessary to help bring the strongest, most certain and most timely containment to this litigation,” he added.
- 21-year payment schedule: Monsanto would make “declining capped annual payments” over a period of up to 21 years to fund the settlement.
- Tiered payouts: Compensation for claimants is expected to vary based on the severity of the illness and the extent of exposure. Early estimates suggest average awards could range from $10,000 to $165,000, with occupational users (like farmers or landscapers) diagnosed with aggressive NHL under the age of 60 potentially receiving the higher end of that scale.
- Broad eligibility: The class includes individuals diagnosed with NHL who were exposed to Roundup prior to the announcement on February 17, 2026, as well as those who may be diagnosed within the next 16 years following final court approval.
The deal serves as a “speed and containment” strategy while Bayer simultaneously prepares for a high-stakes showdown at the U.S. Supreme Court. On April 27, 2026, the High Court is scheduled to hear oral arguments in Monsanto v. Durnell to decide if the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) preempts state-level “failure-to-warn” claims.
A victory for Bayer in Durnell would establish that EPA-approved labels override state laws, potentially providing a “legal shield” that would bar many future lawsuits and drastically alter the long-term outlook of the glyphosate litigation.
Outside of this class settlement, Bayer has also increased its total litigation provisions to approximately €11.8 billion ($12.5 billion) to cover separate agreements involving Roundup and PCB-related cases.
Anderson emphasized that the company chose “speed and containment over a protracted legal battle,” noting that the settlement contains no admission of liability or wrongdoing. The company further argues that the active ingredient, glyphosate, is safe and non-carcinogenic, citing the EPA’s continued approval of the product.
However, while lead plaintiff firms like Seeger Weiss support the agreement, other attorneys representing thousands of victims have called the proposed payouts “exceedingly small” and predict a high number of plaintiffs may choose to opt out to pursue independent trials.
Additionally, the settlement is not yet final.
It must undergo a rigorous court approval process, during which potential class members will be notified and given the opportunity to opt out. If the number of opt-outs is deemed “excessive,” Bayer reserves the right to terminate the agreement entirely.
🚨Bayer has proposed a 7.25 billion dollar settlement for Roundup cancer cases.
The catch?
It covers both current and future cancer claims.
There is a reason Bayer’s stock jumped after the announcement.
This is not a win. pic.twitter.com/uq4uhjl8F2
— MAHA Action (@MAHA_Action) February 17, 2026
Stay informed! Receive breaking news alerts directly to your inbox for free. Subscribe here. https://www.oann.com/alerts
What do YOU think? Click here to jump to the comments!
Sponsored Content Below